Untitled

Loading Events

« All Webinars

“Testing and Treatment of 2020-2021 Seasonal Influenza During the COVID-19 Pandemic”

The CDC Clinician Outreach and Communication Activity (COCA)* presents...”Testing and Treatment of 2020-2021 Seasonal Influenza During the COVID-19 Pandemic”

Influenza surveillance data reported to the World Health Organization’s FluNet platform from three Southern Hemisphere countries (Australia, Chile, and South Africa) indicated low influenza activity during June through August 2020, months that comprise the typical Southern Hemisphere influenza season. The low influenza activity observed in the Southern Hemisphere might reflect the impact of non-pharmaceutical interventions implemented to reduce the spread of SARS-CoV-2, the virus that causes COVID-19. However, it is not possible to predict influenza activity or the severity of the upcoming influenza season in the United States with the potential for co-circulation of influenza viruses and SARS-CoV-2. While vaccination remains the best way to prevent influenza, antiviral medications are an essential adjunct to vaccination—especially for treating outpatients with suspected or confirmed influenza, in persons at high risk for influenza complications, in those with progressive disease, and hospitalized influenza patients.
During this COCA call, clinicians will hear an overview of CDC’s recommendations for health care providers regarding influenza diagnostics and the use of antiviral medications for the 2020-2021 influenza season, including considerations during the ongoing COVID-19 pandemic.

Learning Objectives  |  At the end of this session, participants should be able to:

  1. Review influenza activity since the onset of the COVID-19 pandemic.
  2. Provide background on influenza tests and antivirals for influenza.
  3. Describe influenza testing guidance for patients with acute respiratory illness for the 2020-2021 season, including during community co-circulation of influenza viruses and SARS-CoV-2.
  4. Describe antiviral treatment recommendations for patients with suspected or confirmed influenza for the 2020-2021 season, including during community co-circulation of influenza viruses and SARS-CoV-2.

Presenters:

Angela Campbell, MD, MPH, FIDSA, FPIDS Medical Officer, Influenza Division  |  National Center for Immunization & Respiratory Diseases  |  Centers for Disease Control & Prevention

Timothy Uyeki, MD, MPH, MPP, CAPT, USPHS   |Chief Medical Officer, Influenza Division  |  National Center for Immunization & Respiratory Diseases  |  Centers for Disease Control & Prevention

Continuing Education information: To receive continuing education (CE) for WC2922-091720 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Testing and Treatment of 2020-2021 Seasonal Influenza During the COVID-19 Pandemic, Thursday, September 17, 2020, please visit TCEO and follow these 9 Simple Steps by Monday, October 19, 2020.  To receive continuing education (CE) for WD2922-091720 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Testing and Treatment of 2020-2021 Seasonal Influenza During the COVID-19 Pandemic, Thursday, September 17, 2020, (Web on Demand), please visit TCEO and follow these 9 Simple Steps by Thursday, October 20, 2022.

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.  The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity provides 1.0 contact hour.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 091720.

CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive) 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-20-049-L04-P and enduring JA4008229-0000-20-050-H04-P course category.

This activity has been designated as Knowledge-Based.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor. For Certified Public Health Professionals (CPH), The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1.0 CPH recertification credit for this program.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at race@aavsb.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

* NOTE: This is a supplier and industry resource-sponsored webinar. HealthTrust has not approved and/or endorsed the content. This program may contain the mention of products, services, drugs or brands presented in a case study or comparative format. Such examples are intended for educational and informational purposes and should not be perceived as a HealthTrust endorsement of any particular supplier, product, service, drug, brand or approach.